Xund website preview
medtech Wien, AT 3 sources
Own this company? Claim the page to unlock editing and verified-owner badge.

Xund provides user-friendly health risk assessments and prevention strategies for asymptomatic patients, aiding healthcare professionals in making critical healthcare decisions.

Classification

Wien AT medtech saas b2b ai HealthAIPersonalizedTechnologyInsights

Profile

Founded
2018
Headcount
51-200
Tech stack
MediaWiki, PHP, MySQL
Revenue range
<€1M

Funding

Funding details not yet available.

Business model
💡 Value Proposition

Brings clarity to healthcare decisions by providing simple, user-friendly health risk assessments and guiding asymptomatic patients toward effective prevention strategies.

👥 Customer Segments

Healthcare professionals and their ecosystems, specifically targeting asymptomatic patients for health check and prevention services.

💰 Revenue Model

non-profit/donations

📡 Channels

organic/search

🤝 Key Partnerships

Wikimedia Foundation, Wikimedia chapters globally, technology infrastructure partners.

⚖️ Cost Structure

hosting, technical infrastructure, legal, community support

🏗️ Key Resources

A human-centered mindset integrating technology and medicine, guided by core values of simplicity, quality, safety, and patient value.

⚙️ Key Activities

Developing simple solutions for complex healthcare problems, ensuring product quality and safety, and enabling clients to deliver value to patients.

💬 Customer Relationships

community/self-serve

Strategic analysis
🏁 Competitive landscape

Competes with other reference works and search engines, differentiated by its open-editing model and non-profit status.

🎯 Market pains

Lack of clarity in important healthcare decisions and the need for accessible, user-friendly health risk assessments for asymptomatic patients.

💎 Improvement suggestions
  • Diversify Revenue with Outcome-Based Contracts - Tie a portion of fees to measurable health outcomes (e.g., reduction in ER visits). This
♟️ Strategic implications

What is the current mix of subscription vs. pay-per-use revenue? Understanding the proportion helps prioritize pricing experiments · Are there existing outcome-based pilots with any insurer? If not, what clinical metrics would be most compelling for a pilot? · What is the roadmap for expanding the RAVE LLM to incorporate real-world evidence (RWE) d

🛡️ Credibility notes
  • Regulatory validation - XUND’s Class IIa SaMD status under MDR is a rare, high-barrier credential in the European health-tech space[3]
Team

Team details not yet available.

Investors

No investors recorded yet.

Sources & references

Web verified · 3 sources
Enriched 18 Jun 2026